The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.

Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b ...